Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling

European Journal of Immunology

Volumn 44, Issue 4, 2014, Pages 1200-1212

  Stürner, Klarissa Hanja ^a   Verse, Nina ^a   Yousef, Sara ^a   Martin, Roland ^a,b   Sospedra, Mireia ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

AKBA; Boswellic acids; Th17 cells

Indexed keywords

ACETYL 11 OXO BETA BOSWELLIC ACID; BOSWELLIC ACID; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; SERINE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; POLARIZATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL;

AKBA; BOSWELLIC ACIDS; TH17 CELLS;

ADULT; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTERLEUKIN-17; INTERLEUKIN-1BETA; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS; TRITERPENES; YOUNG ADULT;

EID: 84897970643     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343629     Document Type: Article

References (40)

1. Bouma, G. and Strober, W., The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol 2003. 3: 521-533.
2. Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K., IL-17 and Th17 cells. Annu. Rev. Immunol. 2009. 27: 485-517.
3. Steinman, L., A rush to judgment on Th17. J. Exp. Med. 2008. 205: 1517-1522.
4. Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F. et al., Human Th17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007. 13: 1173-1175.
5. Tzartos, J. S., Friese, M. A., Craner, M. J., Palace, J., Newcombe, J., Esiri, M. M. and Fugger, L., Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008. 172: 146-155.
6. Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A. et al., Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002. 8: 500-508.
7. Ziolkowska, M., Koc, A., Luszczykiewicz, G., Ksiezopolska-Pietrzak, K., Klimczak, E., Chwalinska-Sadowska, H. and Maslinski, W., High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 2000. 164: 2832-2838.
8. Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T. and Fujiyama, Y., Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003. 52: 65-70.
9. Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E. et al., Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007. 204: 1849-1861.
10. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. and Stockinger, B., TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006. 24: 179-189.
11. Wen, Z., Zhong, Z. and Darnell, J. E., Jr., Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995. 82: 241-250.
12. Huang, Y., Li, T., Sane, D. C. and Li, L., IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J. Biol. Chem. 2004. 279: 51697-51703.
13. Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A. and Sallusto, F., Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 2007. 8: 942-949.
14. Zielinski, C. E., Mele, F., Aschenbrenner, D., Jarrossay, D., Ronchi, F., Gattorno, M., Monticelli, S. et al., Pathogen-induced human Th17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012. 484: 514-518.
15. Maitra, U., Davis, S., Reilly, C. M. and Li, L., Differential regulation of Foxp3 and IL-17 expression in CD4 T helper cells by IRAK-1. J. Immunol. 2009. 182: 5763-5769.
16. Moussaieff, A. and Mechoulam, R., Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J. Pharm. Pharmacol. 2009. 61: 1281-1293.
17. Ernst, E., Frankincense: systematic review. BMJ 2008. 337: a2813.
18. Shen, T. and Lou, H. X., Bioactive constituents of myrrh and frankincense, two simultaneously prescribed gum resins in chinese traditional medicine. Chem. Biodivers. 2008. 5: 540-553.
19. Syrovets, T., Gschwend, J. E., Buchele, B., Laumonnier, Y., Zugmaier, W., Genze, F. and Simmet, T., Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J. Biol. Chem. 2005. 280: 6170-6180.
20. Poeckel, D., Tausch, L., George, S., Jauch, J. and Werz, O., 3-O-acetyl-11-keto-boswellic acid decreases basal intracellular Ca2+ levels and inhibits agonist-induced Ca2+ mobilization and mitogen-activated protein kinase activation in human monocytic cells. J. Pharmacol. Exp. Ther. 2006. 316: 224-232.
21. Safayhi, H., Mack, T., Sabieraj, J., Anazodo, M. I., Subramanian, L. R. and Ammon, H. P., Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J. Pharmacol. Exp. Ther. 1992. 261: 1143-1146.
22. Poeckel, D., Niedermeyer, T. H., Pham, H. T., Mikolasch, A., Mundt, S., Lindequist, U., Lalk, M. and Werz, O., Inhibition of human 5-lipoxygenase and anti-neoplastic effects by 2-amino-1, 4-benzoquinones. Med. Chem. 2006. 2: 591-595.
23. Safayhi, H., Rall, B., Sailer, E. R. and Ammon, H. P., Inhibition by boswellic acids of human leukocyte elastase. J. Pharmacol. Exp. Ther. 1997. 281: 460-463.
24. Tausch, L., Henkel, A., Siemoneit, U., Poeckel, D., Kather, N., Franke, L., Hofmann, B. et al., Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense. J. Immunol. 2009. 183: 3433-3442.
25. Siemoneit, U., Hofmann, B., Kather, N., Lamkemeyer, T., Madlung, J., Franke, L., Schneider, G. et al., Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids. Biochem. Pharmacol. 2008. 75: 503-513.
26. Siemoneit, U., Koeberle, A., Rossi, A., Dehm, F., Verhoff, M., Reckel, S., Maier, T. J. et al., Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense. Br. J. Pharmacol. 2011. 162: 147-162.
27. Kunnumakkara, A. B., Nair, A. S., Sung, B., Pandey, M. K. and Aggarwal, B. B., Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol. Cancer. Res. 2009. 7: 118-128.
28. Kebir, H., Ifergan, I., Alvarez, J. I., Bernard, M., Poirier, J., Arbour, N., Duquette, P. and Prat, A., Preferential recruitment of interferon-gamma-expressing Th17 cells in multiple sclerosis. Ann. Neurol. 2009. 66: 390-402.
29. Reppert, S., Boross, I., Koslowski, M., Tureci, O., Koch, S., Lehr, H. A. and Finotto, S., A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat. Comm. 2011. 2: 600.
30. Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J. and Ouyang, W., Interleukin-22: a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007. 445: 648-651.
31. Chizzolini, C., Chicheportiche, R., Alvarez, M., de Rham, C., Roux-Lombard, P., Ferrari-Lacraz, S. and Dayer, J. M., Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 2008. 112: 3696-3703.
32. Boniface, K., Bak-Jensen, K. S., Li, Y., Blumenschein, W. M., McGeachy, M. J., McClanahan, T. K., McKenzie, B. S. et al., Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 2009. 206: 535-548.
33. Yao, C., Sakata, D., Esaki, Y., Li, Y., Matsuoka, T., Kuroiwa, K., Sugimoto, Y. and Narumiya, S., Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 2009. 15: 633-640.
34. Dinarello, C. A., A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur. J. Immunol. 2011. 41: 1203-1217.
35. + T cells. J. Immunol. 2011. 187: 5627-5635.
36. Sha, Y. and Markovic-Plese, S., A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases. Self Nonself. 2011. 2: 35-42.
37. Akhtar, N., Miller, M. J. and Haqqi, T. M., Effect of a herbal-leucine mix on the IL-1beta-induced cartilage degradation and inflammatory gene expression in human chondrocytes. BMC Complement Altern. Med. 2011. 11: 66.
38. Vishal, A. A., Mishra, A. and Raychaudhuri, S. P., A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int. J. Med. Sci. 2011. 8: 615-622.
39. Sengupta, K., Krishnaraju, A. V., Vishal, A. A., Mishra, A., Trimurtulu, G., Sarma, K. V., Raychaudhuri, S. K. and Raychaudhuri, S. P., Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int. J. Med. Sci. 2010. 7: 366-377.
40. Gassmann, M., Grenacher, B., Rohde, B. and Vogel, J., Quantifying Western blots: pitfalls of densitometry. Electrophoresis 2009. 30: 1845-1855.